EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY
Lin Chang 1
David C. Kunkel 2
Brett A. English 3
Beatriz Lindstrom 3
Sharon Skare 3
Charlie Liu 3
Stewart Turner 3
Fabio Cataldi 3
Saleem Desai 4
Donald Lipkis 5
Jan Tack 6
Brooks D Cash 7
Anthony J. Lembo 8
1 David Geffen School of Medicine, UCLA, Los Angeles, United States
2 University of California San Diego, La Jolla, United States
3 Arena Pharmaceuticals, Inc., San Diego, United States
4 Los Angeles Gastroenterology, Northridge, United States
5 Sharp Grossmont Hospital, San Diego, United States
6 University Hospitals Leuven, Leuven, Belgium
7 University of Texas Health Science Center Houston, Houston, United States
8 Beth Israel Deaconess Medical Center, Boston, United States
Topic
Disease Mechanisms, Gut Microbiota
Session
IBS
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]